Skip to main content

Table 7 Fluorescence-activated cell sorting analysis of TBG-Dy uptake

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Cell line or tumor Treatment Dy-positive (%)
MDA-MB-231 Untreated 1.9
MDA-MB-231 TBG-Dy 1× 14.4
MDA-MB-231 TBG-Dy 2× 21.5
SUM-149 Untreated 0.9
SUM-149 TBG-Dy 13.1
SUM-149 tumor 1 Untreated 1.2
SUM-149 tumor 2 i.v. TBG-Dy 36.0
SUM-149 tumor 3 i.v. TBG-Dy 37.1
SUM-149 tumor 4 i.v. TBG-Dy 28.5
MDA-MB-231 tumor 1 Untreated 1.7
MDA-MB-231 tumor 2 i.v. TBG-Dy 11.0
  1. Dy, dysprosium; i.v., intravenous; TBG, tenfibgen.